Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
(Date:7/24/2014)... July 24, 2014 2014 Deep ... Industryā€¯ is a professional and in-depth research report ... Potassium Sulphate basic information, including its definition, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that ... from 17 different countries will converge on the ... Valley for an intensive, experiential program focused on ... The highly selective school, currently running its sixth ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... Abstract , ... in the biological sciences. In drug discovery research, immunoassays ... culture supernatants of treated cells. However, scientists often avoid ... cumbersome manipulations. Applied Biosystems has developed a singlestep, mix-and-read ...
... Purpose , ... of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) ... of assessing inter-individual and intra-individual metabolism variability. To be of ... to monitor these drugs is fast and easy to perform, ...
... Purpose , ... plays an important role in a number of functions, including the ... characterized by impaired, reduced or total absence of peroxisomes in cells, ... and hexacosanoic acids, in plasma. Some variants of these disorders are ...
Cached Biology Technology:Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 2Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 3Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 4Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 5A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 2A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 3A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 4
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... to biobanks vast collections of human tissue samples that ... have a right to basic information about how their donations ... a new paper. The idea behind biobanks is that ... to medical records and other health information, can yield discoveries ...
... and terrorist plots are usually the preserve of Hollywood ... is the stuff of real life. As controversy about ... new paper argues for a complete overhaul of current ... Reconfiguring Global Responses to Influenza, by Dr Paul Forster, ...
... modify their body movements to be in tune with others, ... to be in synchrony with their peers. For example, we ... unison at the end of a concert. This phenomenon is ... the RIKEN Brain Science Institute report today that pairs of ...
Cached Biology News:Safeguards needed for tissue donors 2Pandemic controversies: The global response to pandemic influenza must change 2Primates too can move in unison 2
... special preparation of bovine pancreatic DNase I that ... DNA molecules. In the presence of Mn2+ and ... breaks at random sites in DNA. The average ... by the enzyme concentration and incubation time. This ...
... protease from human rhinovirus (HRV 3C) is ... line of restriction grade proteases. The recombinant ... protein, which recognizes the same cleavage site ... 22 KDa size of the protease, optimal ...
... Thermo Hybaid's unique Electro-4 design allows ... the Electro-4 it is possible to run ... tank, by stacking up to four,horizontal gels. ... adjustable according to the number of gels ...
... The IEC Centra CL3 series ... in typical research and clinical applications ... broad accessory package includes quick connect ... An advanced yet intuitive interface allows ...
Biology Products: